enVVeno Medical Corp. Files 8-K on Delisting Concerns
Ticker: NVNO · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1661053
| Field | Detail |
|---|---|
| Company | Envveno Medical Corp (NVNO) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, 8-k
TL;DR
enVVeno Medical Corp. might be delisted - 8-K filed.
AI Summary
enVVeno Medical Corporation (formerly Hancock Jaffe Laboratories, Inc.) filed an 8-K on October 10, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and also filed financial statements and exhibits. The report covers events as of October 7, 2025. The company is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This filing indicates potential issues with enVVeno Medical Corp.'s continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's market presence and investor accessibility.
Key Players & Entities
- enVVeno Medical Corporation (company) — Registrant
- Hancock Jaffe Laboratories, Inc. (company) — Former company name
- October 7, 2025 (date) — Earliest event reported date
- October 10, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Irvine, California (location) — Principal executive offices
FAQ
What specific listing rule or standard has enVVeno Medical Corporation failed to satisfy?
The filing indicates a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard in the provided text.
What is the significance of the 'Transfer of Listing' mentioned in the filing?
The filing mentions 'Transfer of Listing' as an item of information, but the provided text does not detail the specifics of any such transfer.
When was enVVeno Medical Corporation formerly known as Hancock Jaffe Laboratories, Inc.?
The date of the name change from Hancock Jaffe Laboratories, Inc. to enVVeno Medical Corporation was December 15, 2015.
What is the SEC file number for enVVeno Medical Corporation?
The SEC file number for enVVeno Medical Corporation is 001-38325.
What are the principal executive offices of enVVeno Medical Corporation?
The principal executive offices of enVVeno Medical Corporation are located at 70 Doppler, Irvine, California 92618.
Filing Stats: 748 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2025-10-10 06:30:31
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share NVNO The NASDAQ Stock Mar
- $1.00 — Company's common stock has fallen below $1.00 per share for 30 consecutive business d
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-25-017691.txt ( ) — 197KB
- nvno-20251007.xsd (EX-101.SCH) — 3KB
- nvno-20251007_lab.xml (EX-101.LAB) — 33KB
- nvno-20251007_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 enVVeno Medical Corporation (Exact name of registrant as specified in its charter) Delaware 001-38325 33-0936180 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 70 Doppler Irvine , California 92618 (Address of principal executive offices) (Zip Code) (949) 261-2900 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.00001 per share NVNO The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On October 7, 2025, enVVeno Medical Corporation (the "Company") received notification from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of Nasdaq Listing Rules. Nasdaq's notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until April 6, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must close at or above $1.00 per share for a minimum of 10 consecutive trading days (which period may be extended to greater than 10 consecutive trading days at the sole discretion of Nasdaq) prior to April 6, 2026. In the event the Company does not regain compliance by April 6, 2026, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify for the additional 180-day period, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on the Nasdaq Capital Market until the completion of the appeal process. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVVENO MEDICAL CORPORATION Dated: October 10, 2025 /s/ Robert A. Berman Robert A. Berman Chief Executive Officer